Table 4. Myocardial collagen, periostin and tissue metalloproteinase inhibitor-1 concentrations.
| SHAM (n= 4) | SHAM-S (n= 5) | MI (n= 6) | MI -S (n= 6) | p MI | p S | PMIxS | |
|---|---|---|---|---|---|---|---|
| Periostin/GAPDH* | 0.001 ± 0.0006 | 0.002 ± 0.001ϕ | 0.165 ± 0.113•,ƒ | 0.045 ± 0.023 | <0.001 | 0.360 | 0.002 |
| Type 1 collagen/GAPDH | 1.366 ± 0.182 | 2.918 ± 1.416 | 4.192 ± 1.183ƒ | 3.001 ± 1.028 | 0.014 | 0.738 | 0.019 |
| Type 3 collagen/GAPDH* | 1.003 ± 0.183 | 1.469 ± 0.937 | 2.618 ± 1.152•,ƒ | 1.568 ± 0.391 | 0.005 | 0.548 | 0.045 |
| TIMP-1 (pg/g of protein)* | 21.2 ± 4.3 | 32.9 ± 14.4 | 32.5 ± 14.1 | 150.7 ± 136.7 | 0.010 | 0.008 | 0.149 |
| MMP-9 active/total | 0.48 ± 0.35 | 0.85 ± 0.10 | 0.78 ± 0.23 | 0.84 ± 0.1 | 0.200 | 0.062 | 0.179 |
| MMP-2 active/total | 0.75 ± 0.1 | 0.68 ± 0.1 | 0.57 ± 0.1 | 0.57 ± 0.1 | 0.001 | 0.426 | 0.422 |
S: spironolactone; MI: myocardial infarction; MMP: matrix metalloproteinase; TIMP-1: tissue metalloproteinase inhibitor-1. * data normalized for statistical analysis.
When interactions were observed, symbols show the significant differences (• MI≠MI-S; ƒ MI≠SHAM and ϕ SHAM-S≠MI-S)